Just two days after starting at the FDA, the agency’s Chief Counsel Hilary Perkins is signing off, effective immediately. | ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Following a fire at a Bayer executive’s New Jersey home earlier this month, at least eight agencies—including the Federal ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...